메뉴 건너뛰기




Volumn 126, Issue 23, 2013, Pages 4568-4574

Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients

Author keywords

Advanced cirrhosis; Direct antiviral agents; Elderly; Hepatitis C virus; Hepatocellular carcinoma; Interferon free treatment; Liver transplant

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR;

EID: 84888210472     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131127     Document Type: Review
Times cited : (7)

References (100)
  • 1
    • 0030931156 scopus 로고    scopus 로고
    • Hepatitis C and hepatocellular carcinoma
    • Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (3 Suppl 1): 34S-38S.
    • (1997) Hepatology , vol.26 , Issue.3 SUPPL. 1
    • Di Bisceglie, A.M.1
  • 2
    • 84860287080 scopus 로고    scopus 로고
    • Epidemiology of viral hepatitis and hepatocellular carcinoma
    • El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
    • (2012) Gastroenterology , vol.142 , pp. 1264-1273
    • El-Serag, H.B.1
  • 3
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • Van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3    Wedemeyer, H.4    Dufour, J.F.5    Lammert, F.6
  • 10
    • 83555163652 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    • Kumada H, Toyoda J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
    • (2012) J Hepatol , vol.56 , pp. 78-84
    • Kumada, H.1    Toyoda, J.2    Okanoue, T.3    Chayama, K.4    Tsubouchi, H.5    Hayashi, N.6
  • 11
    • 77958105927 scopus 로고    scopus 로고
    • New antiviral therapies for chronic hepatitis C
    • Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4: 548-561.
    • (2010) Hepatol Int , vol.4 , pp. 548-561
    • Kanda, T.1    Imazeki, F.2    Yokosuka, O.3
  • 12
    • 84862850805 scopus 로고    scopus 로고
    • APASL consensus statements and management algorithms for hepatitis C virus infection
    • Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-435.
    • (2012) Hepatol Int , vol.6 , pp. 409-435
    • Omata, M.1    Kanda, T.2    Yu, M.L.3    Yokosuka, O.4    Lim, S.G.5    Jafri, W.6
  • 13
    • 84884257232 scopus 로고    scopus 로고
    • Treatment of hepatitis C virus infection in the future
    • Kanda T, Yokosuka O, Omata M. Treatment of hepatitis C virus infection in the future. Clin Transl Med 2013; 2: 9.
    • (2013) Clin Transl Med , vol.2 , pp. 9
    • Kanda, T.1    Yokosuka, O.2    Omata, M.3
  • 14
    • 0028876371 scopus 로고
    • Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
    • Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
    • (1995) Lancet , vol.346 , pp. 1051-1055
    • Nishiguchi, S.1    Kuroki, T.2    Nakatani, S.3    Morimoto, H.4    Takeda, T.5    Nakajima, S.6
  • 15
    • 0033520109 scopus 로고    scopus 로고
    • Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy
    • Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999; 131: 174-181.
    • (1999) Ann Intern Med , vol.131 , pp. 174-181
    • Yoshida, H.1    Shiratori, Y.2    Moriyama, M.3    Arakawa, Y.4    Ide, T.5    Sata, M.6
  • 16
    • 17144455384 scopus 로고    scopus 로고
    • Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
    • Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524.
    • (2000) Ann Intern Med , vol.132 , pp. 517-524
    • Shiratori, Y.1    Imazeki, F.2    Moriyama, M.3    Yano, M.4    Arakawa, Y.5    Yokosuka, O.6
  • 17
    • 10744229781 scopus 로고    scopus 로고
    • Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C
    • 425-230
    • Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-230.
    • (2004) Gut , vol.53
    • Yoshida, H.1    Tateishi, R.2    Arakawa, Y.3    Sata, M.4    Fujiyama, S.5    Nishiguchi, S.6
  • 18
    • 59849093175 scopus 로고    scopus 로고
    • Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
    • Lok AS, Seef LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148.
    • (2009) Gastroenterology , vol.136 , pp. 138-148
    • Lok, A.S.1    Seef, L.B.2    Morgan, T.R.3    Di Bisceglie, A.M.4    Sterling, R.K.5    Curto, T.M.6
  • 20
    • 79952316752 scopus 로고    scopus 로고
    • Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C
    • Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-849.
    • (2011) Gastroenterology , vol.140 , pp. 840-849
    • Lok, A.S.1    Everhart, J.E.2    Wright, E.C.3    Di Bisceglie, A.M.4    Kim, H.Y.5    Sterling, R.K.6
  • 21
    • 0035975595 scopus 로고    scopus 로고
    • Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene
    • Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 2001; 288: 379-390.
    • (2001) Virology , vol.288 , pp. 379-390
    • Basu, A.1    Meyer, K.2    Ray, R.B.3    Ray, R.4
  • 22
    • 84888210106 scopus 로고    scopus 로고
    • Interferons in clinical trials
    • In Omata M, Kanda T, eds. London, UK: Future Medicine e-Book
    • Kanda T, Yokosuka O, Omata M. Interferons in clinical trials. In Omata M, Kanda T, eds. Emerging therapeutic options for hepatitis C. London, UK: Future Medicine e-Book; 2013: 7-18.
    • (2013) Emerging therapeutic options for hepatitis C , pp. 7-18
    • Kanda, T.1    Yokosuka, O.2    Omata, M.3
  • 23
    • 0015523596 scopus 로고
    • Broad-spectrum activity of virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide
    • Sidwell R, Huffman JH, Khare L, Allen LB, Witlowski JT, Robins RK. Broad-spectrum activity of virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 1972; 117: 705-706.
    • (1972) Science , vol.117 , pp. 705-706
    • Sidwell, R.1    Huffman, J.H.2    Khare, L.3    Allen, L.B.4    Witlowski, J.T.5    Robins, R.K.6
  • 25
    • 0034532953 scopus 로고    scopus 로고
    • The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
    • Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375-1379.
    • (2000) Nat Med , vol.6 , pp. 1375-1379
    • Crotty, S.1    Maag, D.2    Arnold, J.J.3    Zhong, W.4    Lau, J.Y.5    Hong, Z.6
  • 26
    • 0036333636 scopus 로고    scopus 로고
    • Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system
    • Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76: 8505-8517.
    • (2002) J Virol , vol.76 , pp. 8505-8517
    • Contreras, A.M.1    Hiasa, Y.2    He, W.3    Terella, A.4    Schmidt, E.V.5    Chung, R.T.6
  • 27
    • 11144358183 scopus 로고    scopus 로고
    • Synergic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha
    • Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, et al. Synergic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004; 189: 1129-1139.
    • (2004) J Infect Dis , vol.189 , pp. 1129-1139
    • Tanabe, Y.1    Sakamoto, N.2    Enomoto, N.3    Kurosaki, M.4    Ueda, E.5    Maekawa, S.6
  • 28
    • 8444233615 scopus 로고    scopus 로고
    • Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: Ribavirin induces mutagenesis in HCV RNA
    • Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y, Shimada H, et al. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 2004; 11: 479-487.
    • (2004) J Viral Hepat , vol.11 , pp. 479-487
    • Kanda, T.1    Yokosuka, O.2    Imazeki, F.3    Tanaka, M.4    Shino, Y.5    Shimada, H.6
  • 29
    • 0035824671 scopus 로고    scopus 로고
    • Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin
    • Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276: 46094-46098.
    • (2001) J Biol Chem , vol.276 , pp. 46094-46098
    • Maag, D.1    Castro, C.2    Hong, Z.3    Cameron, C.E.4
  • 30
    • 85047692907 scopus 로고    scopus 로고
    • The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA
    • Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003; 310: 332-342.
    • (2003) Virology , vol.310 , pp. 332-342
    • Zhou, S.1    Liu, R.2    Baroudy, B.M.3    Malcolm, B.A.4    Reyes, G.R.5
  • 31
    • 77949773445 scopus 로고    scopus 로고
    • ITPA gene variants protect against anemia in patients treated for chronic hepatitis C
    • Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shinna KV, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
    • (2010) Nature , vol.464 , pp. 405-408
    • Fellay, J.1    Thompson, A.J.2    Ge, D.3    Gumbs, C.E.4    Urban, T.J.5    Shinna, K.V.6
  • 32
    • 0033024781 scopus 로고    scopus 로고
    • Ribavirin polarizes human T cell responses toward a Type 1 cytokine profile
    • Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, et al. Ribavirin polarizes human T cell responses toward a Type 1 cytokine profile. J Hepatol 1999; 30: 376-382.
    • (1999) J Hepatol , vol.30 , pp. 376-382
    • Tam, R.C.1    Pai, B.2    Bard, J.3    Lim, C.4    Averett, D.R.5    Phan, U.T.6
  • 33
    • 0038032916 scopus 로고    scopus 로고
    • Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syntial virus-infected epithelial cells
    • Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, Casola A, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syntial virus-infected epithelial cells. J Virol 2003; 77: 5933-5947.
    • (2003) J Virol , vol.77 , pp. 5933-5947
    • Zhang, Y.1    Jamaluddin, M.2    Wang, S.3    Tian, B.4    Garofalo, R.P.5    Casola, A.6
  • 34
    • 78751545582 scopus 로고    scopus 로고
    • Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
    • Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TL. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53: 32-41.
    • (2011) Hepatology , vol.53 , pp. 32-41
    • Thomas, E.1    Feld, J.J.2    Li, Q.3    Hu, Z.4    Fried, M.W.5    Liang, T.L.6
  • 35
    • 34147207791 scopus 로고    scopus 로고
    • A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
    • Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559.
    • (2007) Gut , vol.56 , pp. 553-559
    • Yu, M.L.1    Dai, C.Y.2    Huang, J.F.3    Hou, N.J.4    Lee, L.P.5    Hsieh, M.Y.6
  • 36
    • 84858432382 scopus 로고    scopus 로고
    • A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
    • Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19 Suppl2: 1-26.
    • (2012) J Viral Hepat , vol.19 , Issue.SUPPL. 2 , pp. 1-26
    • Jacobson, I.M.1    Pawlotsky, J.M.2    Afdhal, N.H.3    Dusheiko, G.M.4    Forns, X.5    Jensen, D.M.6
  • 37
    • 54349127407 scopus 로고    scopus 로고
    • Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis
    • Syed E, Rahbin N, Weiland O, Carlsson T, Oksanen A, Birk M, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol 2008; 43: 1378-1386.
    • (2008) Scand J Gastroenterol , vol.43 , pp. 1378-1386
    • Syed, E.1    Rahbin, N.2    Weiland, O.3    Carlsson, T.4    Oksanen, A.5    Birk, M.6
  • 38
    • 75449106958 scopus 로고    scopus 로고
    • Efficacy and safety of peginterferon alfa-2a (40kD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis
    • Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40kD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-397.
    • (2010) Hepatology , vol.51 , pp. 388-397
    • Bruno, S.1    Shiffman, M.L.2    Roberts, S.K.3    Gane, E.J.4    Messinger, D.5    Hadziyannis, S.J.6
  • 39
    • 84888223197 scopus 로고    scopus 로고
    • Study of peginterferon alfa-2b plus ribavirin combination therapy in type C compensed liver cirrhosis
    • Kumada H, Okanoue T. Study of peginterferon alfa-2b plus ribavirin combination therapy in type C compensed liver cirrhosis. Kanzo (JPN) 2012; 53: 803-813.
    • (2012) Kanzo (JPN) , vol.53 , pp. 803-813
    • Kumada, H.1    Okanoue, T.2
  • 40
    • 84879141644 scopus 로고    scopus 로고
    • Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systemic review
    • Bota S, Sporea I, Sirli R, Popescu A, Neghina AM, Danila M, et al. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systemic review. World J Gastroenterol 2013; 5: 120-126.
    • (2013) World J Gastroenterol , vol.5 , pp. 120-126
    • Bota, S.1    Sporea, I.2    Sirli, R.3    Popescu, A.4    Neghina, A.M.5    Danila, M.6
  • 41
    • 84879843839 scopus 로고    scopus 로고
    • Magnitude of contrast-enhanced ultrasonography as a noninvasive predictor for hepatic fibrosis: Comparison with liver stiffness measurement and serum-based models
    • Tawada A, Maruyama H, Kamezaki H, Shimada T, Ishibashi H, Takahashi M, et al. Magnitude of contrast-enhanced ultrasonography as a noninvasive predictor for hepatic fibrosis: comparison with liver stiffness measurement and serum-based models. Hepatol Int 2013; 7: 749-757.
    • (2013) Hepatol Int , vol.7 , pp. 749-757
    • Tawada, A.1    Maruyama, H.2    Kamezaki, H.3    Shimada, T.4    Ishibashi, H.5    Takahashi, M.6
  • 42
    • 84876319936 scopus 로고    scopus 로고
    • Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response
    • Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. Dig Dis Sci 2013; 53: 556-561.
    • (2013) Dig Dis Sci , vol.53 , pp. 556-561
    • Kee, K.M.1    Wang, J.H.2    Hung, C.H.3    Chen, C.H.4    Lee, C.M.5    Lu, S.N.6
  • 43
    • 84879158172 scopus 로고    scopus 로고
    • Platelet count and sustained virological response in hepatitis C treatment
    • Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, et al. Platelet count and sustained virological response in hepatitis C treatment. World J Hepatol 2003; 5: 182-188.
    • (2003) World J Hepatol , vol.5 , pp. 182-188
    • Kanda, T.1    Kato, K.2    Tsubota, A.3    Takada, N.4    Nishino, T.5    Mikami, S.6
  • 46
    • 84874107832 scopus 로고    scopus 로고
    • Perspectives and challenges of interferon-free therapy for chronic hepatitis C
    • Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58: 583-592.
    • (2013) J Hepatol , vol.58 , pp. 583-592
    • Lange, C.M.1    Zeuzem, S.2
  • 48
    • 84865436729 scopus 로고    scopus 로고
    • Analysis of the factors motivating HCV-infected patients to accept interferon therapy
    • Nagao Y, Sata M. Analysis of the factors motivating HCV-infected patients to accept interferon therapy. BMC Res Notes 2012; 5: 470.
    • (2012) BMC Res Notes , vol.5 , pp. 470
    • Nagao, Y.1    Sata, M.2
  • 49
    • 84875268532 scopus 로고    scopus 로고
    • Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1
    • Miyauchi T, Kanda T, Imazeki F, Mikata R, Tawada A, Arai M, et al. Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. Hepatol Int 2013; 7: 144-152.
    • (2013) Hepatol Int , vol.7 , pp. 144-152
    • Miyauchi, T.1    Kanda, T.2    Imazeki, F.3    Mikata, R.4    Tawada, A.5    Arai, M.6
  • 50
    • 0036788338 scopus 로고    scopus 로고
    • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    • McHutchison JG, Manns M, Patel K, Poynard T, Lidsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
    • (2002) Gastroenterology , vol.123 , pp. 1061-1069
    • McHutchison, J.G.1    Manns, M.2    Patel, K.3    Poynard, T.4    Lidsay, K.L.5    Trepo, C.6
  • 51
    • 84874104694 scopus 로고    scopus 로고
    • In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters
    • Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, et al. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 2013; 41: 668-681.
    • (2013) Drug Metab Dispos , vol.41 , pp. 668-681
    • Chu, X.1    Cai, X.2    Cui, D.3    Tang, C.4    Ghosal, A.5    Chan, G.6
  • 52
    • 84855232974 scopus 로고    scopus 로고
    • Hepatitis C virus-human immunodeficiency virus coinfection
    • Sulkowski MS. Hepatitis C virus-human immunodeficiency virus coinfection. Liver Int 2012; 32 Suppl 1: 129-134.
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 129-134
    • Sulkowski, M.S.1
  • 53
    • 84875275752 scopus 로고    scopus 로고
    • Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997
    • van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chene G, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013; 144: 751-760.
    • (2013) Gastroenterology , vol.144 , pp. 751-760
    • van der Helm, J.1    Geskus, R.2    Sabin, C.3    Meyer, L.4    Del Amo, J.5    Chene, G.6
  • 55
    • 3342892905 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    • Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
    • (2004) N Engl J Med , vol.351 , pp. 451-459
    • Chung, R.T.1    Andersen, J.2    Volberding, P.3    Robbins, G.K.4    Liu, T.5    Sherman, K.E.6
  • 56
    • 10344230440 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized control trial
    • Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized control trial. JAMA 2004; 292: 2839-2848.
    • (2004) JAMA , vol.292 , pp. 2839-2848
    • Carrat, F.1    Bani-Sadr, F.2    Pol, S.3    Rosenthal, E.4    Lunel-Fabiani, F.5    Benzekri, A.6
  • 57
    • 4444270265 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
    • Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-F36.
    • (2004) AIDS , vol.18
    • Laguno, M.1    Murillas, J.2    Blanco, J.L.3    Martinez, E.4    Miquel, R.5    Sanchez-Tapias, J.M.6
  • 58
    • 34848813462 scopus 로고    scopus 로고
    • Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial
    • Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-982.
    • (2007) AIDS Res Hum Retroviruses , vol.23 , pp. 972-982
    • Nunez, M.1    Miralles, C.2    Berdun, M.A.3    Losada, E.4    Aguirrebengoa, K.5    Ocampo, A.6
  • 59
    • 58949099266 scopus 로고    scopus 로고
    • Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
    • Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22-31.
    • (2009) Hepatology , vol.49 , pp. 22-31
    • Laguno, M.1    Cifuentes, C.2    Murillas, J.3    Veloso, S.4    Larrousse, M.5    Payeras, A.6
  • 60
    • 84863393745 scopus 로고    scopus 로고
    • Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons
    • Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin J Infect Dis 2012; 54: 979-983.
    • (2012) Clin J Infect Dis , vol.54 , pp. 979-983
    • Thomas, D.L.1    Bartlett, J.G.2    Peters, M.G.3    Sherman, K.E.4    Sulkowski, M.S.5    Pham, P.A.6
  • 61
    • 84856869185 scopus 로고    scopus 로고
    • A review of drug interactions with boceprevir and telaprevir: Implications for HIV and transplants
    • Wilby KJ, Greanya ED, Ford JAE, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplants. Ann Hepatol 2012; 11: 179-185.
    • (2012) Ann Hepatol , vol.11 , pp. 179-185
    • Wilby, K.J.1    Greanya, E.D.2    Ford, J.A.E.3    Yoshida, E.M.4    Partovi, N.5
  • 62
    • 80855146132 scopus 로고    scopus 로고
    • Clinical pharmacology of BOC: Metabolism, excretion, and drug-drug interactions (Session34-oral abstract)
    • Feb 27-Mar 2, 2011, Boston, USA (Accessed April 23, 2013 at
    • Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions (Session34-oral abstract) 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA (Accessed April 23, 2013 at http://www. retroconference. org/2011/Abstracts/41140. htm.).
    • 18th Conference on Retroviruses and Opportunistic Infections
    • Kasserra, C.1    Hughes, E.2    Treitel, M.3    Gupta, S.4    O'Mara, E.5
  • 63
    • 84878475234 scopus 로고    scopus 로고
    • Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C
    • Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605.
    • (2013) Am J Transplant , vol.13 , pp. 1601-1605
    • Fontana, R.J.1    Hughes, E.A.2    Bifano, M.3    Appelman, H.4    Dimitrova, D.5    Hindes, R.6
  • 64
    • 84870397497 scopus 로고    scopus 로고
    • Liver transplantation in the setting of chronic HCV
    • Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012; 26: 531-548.
    • (2012) Best Pract Res Clin Gastroenterol , vol.26 , pp. 531-548
    • Terrault, N.1
  • 65
    • 84874529088 scopus 로고    scopus 로고
    • Living-donor liver transplantation and hepatitis C
    • Akamatsu N, Sugawara Y. Living-donor liver transplantation and hepatitis C. HPB Surg 2013; 2013: 985972.
    • (2013) HPB Surg , vol.2013 , pp. 985972
    • Akamatsu, N.1    Sugawara, Y.2
  • 66
    • 23044500773 scopus 로고    scopus 로고
    • Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy
    • Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
    • (2005) Hepatology , vol.42 , pp. 255-262
    • Everson, G.T.1    Trotter, J.2    Forman, L.3    Kugelmas, M.4    Halprin, A.5    Fey, B.6
  • 67
    • 33845647232 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study
    • Iacobellis A, Siliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2a and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212.
    • (2007) J Hepatol , vol.46 , pp. 206-212
    • Iacobellis, A.1    Siliano, M.2    Perri, F.3    Annicchiarico, B.E.4    Leandro, G.5    Caruso, N.6
  • 68
    • 42949108594 scopus 로고    scopus 로고
    • Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhosis
    • Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhosis. Aliment Pharmacol Ther 2008; 27: 1081-1085.
    • (2008) Aliment Pharmacol Ther , vol.27 , pp. 1081-1085
    • Tekin, F.1    Gunsar, F.2    Karasu, Z.3    Akarca, U.4    Ersoz, G.5
  • 69
    • 70349582718 scopus 로고    scopus 로고
    • An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant
    • Massoumi H, Elsiesy H, Khaitova V, Peterson B, Norkus E, Grewal P, et al. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation 2009; 88: 729-735.
    • (2009) Transplantation , vol.88 , pp. 729-735
    • Massoumi, H.1    Elsiesy, H.2    Khaitova, V.3    Peterson, B.4    Norkus, E.5    Grewal, P.6
  • 70
    • 61749085030 scopus 로고    scopus 로고
    • Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study
    • Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-728.
    • (2009) J Hepatol , vol.50 , pp. 719-728
    • Carrion, J.A.1    Martinez-Bauer, E.2    Crespo, G.3    Ramirez, S.4    Perez-del-Pulgar, S.5    Garcia-Valdecasas, J.C.6
  • 71
    • 84876713834 scopus 로고    scopus 로고
    • A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation
    • Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS Jr, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-1762.
    • (2013) Hepatology , vol.57 , pp. 1752-1762
    • Everson, G.T.1    Terrault, N.A.2    Lok, A.S.3    Rodrigo, D.R.4    Brown Jr., R.S.5    Saab, S.6
  • 72
    • 70349292099 scopus 로고    scopus 로고
    • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    • Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
    • (2009) Nature , vol.461 , pp. 399-401
    • Ge, D.1    Fellay, J.2    Thompson, A.J.3    Simon, J.S.4    Shianna, K.V.5    Urban, T.J.6
  • 73
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    • Tanaka Y, Nishida N, Sugiyama M, Kuroki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
    • (2009) Nat Genet , vol.41 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3    Kuroki, M.4    Matsuura, K.5    Sakamoto, N.6
  • 74
    • 70349548852 scopus 로고    scopus 로고
    • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    • Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
    • (2009) Nat Genet , vol.41 , pp. 1100-1104
    • Suppiah, V.1    Moldovan, M.2    Ahlenstiel, G.3    Berg, T.4    Weltman, M.5    Abate, M.L.6
  • 75
    • 79960202529 scopus 로고    scopus 로고
    • Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients
    • Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, Fujiwara K, et al. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol 2011; 46: 955-961.
    • (2011) Scand J Gastroenterol , vol.46 , pp. 955-961
    • Nakamoto, S.1    Kanda, T.2    Imazeki, F.3    Wu, S.4    Arai, M.5    Fujiwara, K.6
  • 76
    • 83155167582 scopus 로고    scopus 로고
    • Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients
    • Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, Imazeki F, et al. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One 2011; 6: e28617.
    • (2011) PLoS One , vol.6
    • Miyamura, T.1    Kanda, T.2    Nakamoto, S.3    Wu, S.4    Fujiwara, K.5    Imazeki, F.6
  • 77
    • 84868607491 scopus 로고    scopus 로고
    • Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin
    • Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, et al. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses 2012, 4: 1264-1278.
    • (2012) Viruses , vol.4 , pp. 1264-1278
    • Miyamura, T.1    Kanda, T.2    Nakamoto, S.3    Wu, S.4    Jiang, X.5    Arai, M.6
  • 78
    • 78049470128 scopus 로고    scopus 로고
    • Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C
    • Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.
    • (2010) Gastroenterology , vol.139 , pp. 1577-1585
    • Fukuhara, T.1    Taketomi, A.2    Motomura, T.3    Okano, S.4    Ninomiya, A.5    Abe, T.6
  • 79
    • 0028961434 scopus 로고
    • Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients
    • Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-655.
    • (1995) Hepatology , vol.21 , pp. 650-655
    • Takano, S.1    Yokosuka, O.2    Imazeki, F.3    Tagawa, M.4    Omata, M.5
  • 80
    • 79961111356 scopus 로고    scopus 로고
    • Occurrence of hepatocellular carcinoma was not rare event during and immediately after antiviral treatment in Japanese HCV-positive patients
    • Kanda T, Imazeki F, Mikami S, Kato K, Shimada N, Yonemitsu Y, et al. Occurrence of hepatocellular carcinoma was not rare event during and immediately after antiviral treatment in Japanese HCV-positive patients. Oncology 2011; 80: 366-372.
    • (2011) Oncology , vol.80 , pp. 366-372
    • Kanda, T.1    Imazeki, F.2    Mikami, S.3    Kato, K.4    Shimada, N.5    Yonemitsu, Y.6
  • 81
    • 84878428622 scopus 로고    scopus 로고
    • Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis
    • Tarao K, Ohkawa S, Miyagi Y, Morinaga S, Ohshige K, Yamamoto N, et al. Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis. Scand J Gastroenterol 2013; 48: 729-735.
    • (2013) Scand J Gastroenterol , vol.48 , pp. 729-735
    • Tarao, K.1    Ohkawa, S.2    Miyagi, Y.3    Morinaga, S.4    Ohshige, K.5    Yamamoto, N.6
  • 82
    • 0037452519 scopus 로고    scopus 로고
    • Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus
    • Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306.
    • (2003) Ann Intern Med , vol.138 , pp. 299-306
    • Shiratori, Y.1    Shiina, S.2    Teratani, T.3    Imamura, M.4    Obi, S.5    Sato, S.6
  • 83
    • 33646778095 scopus 로고    scopus 로고
    • Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma
    • Akamatsu M, Yoshida H, Shiina S, Teratani T, Obi S, Tateishi R, et al. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 2006; 26: 536-542.
    • (2006) Liver Int , vol.26 , pp. 536-542
    • Akamatsu, M.1    Yoshida, H.2    Shiina, S.3    Teratani, T.4    Obi, S.5    Tateishi, R.6
  • 85
    • 33750369259 scopus 로고    scopus 로고
    • Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    • Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006; 55: 1631-1638.
    • (2006) Gut , vol.55 , pp. 1631-1638
    • Sherman, M.1    Yoshida, E.M.2    Deschenes, M.3    Krajden, M.4    Bain, V.G.5    Peltekian, K.6
  • 86
    • 67349172961 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    • Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-1628.
    • (2009) Gastroenterology , vol.136 , pp. 1618-1628
    • Poynard, T.1    Colombo, M.2    Bruix, J.3    Schiff, E.4    Terg, R.5    Flamm, S.6
  • 87
    • 84871356915 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy
    • Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, et al. Peginterferon alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy. Int J Med Sci 2013; 10: 43-49.
    • (2013) Int J Med Sci , vol.10 , pp. 43-49
    • Kanda, T.1    Nakamoto, S.2    Nishino, T.3    Takada, N.4    Tsubota, A.5    Kato, K.6
  • 88
    • 80052116134 scopus 로고    scopus 로고
    • Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
    • Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-889.
    • (2011) Gastroenterology , vol.141 , pp. 881-889
    • Foster, G.R.1    Hezode, C.2    Bronowicki, J.P.3    Carosi, G.4    Weiland, O.5    Verlinden, L.6
  • 92
    • 84878976866 scopus 로고    scopus 로고
    • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial
    • Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107.
    • (2013) Lancet , vol.381 , pp. 2100-2107
    • Kowdley, K.V.1    Lawitz, E.2    Crespo, I.3    Hassanein, T.4    Davis, M.N.5    Demicco, M.6
  • 93
    • 84876740954 scopus 로고    scopus 로고
    • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial
    • Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408.
    • (2013) Lancet Infect Dis , vol.13 , pp. 401-408
    • Lawitz, E.1    Lalezari, J.P.2    Hassanein, T.3    Kowdley, K.V.4    Poordad, F.F.5    Sheikh, A.M.6
  • 94
    • 84855240877 scopus 로고    scopus 로고
    • Treatment of patients with genotype 3 chronic hepatitis C-current and future therapies
    • Sarin SK, Kumar CK. Treatment of patients with genotype 3 chronic hepatitis C-current and future therapies. Liver Int 2012; 32 Suppl 1: 141-145.
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 141-145
    • Sarin, S.K.1    Kumar, C.K.2
  • 95
    • 84855242247 scopus 로고    scopus 로고
    • What's new in HCV genotype 2 treatment
    • Mangia A, Mottola L. What's new in HCV genotype 2 treatment. Liver Int 2012; 32 Suppl 1: 135-140.
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 135-140
    • Mangia, A.1    Mottola, L.2
  • 96
    • 82755182674 scopus 로고    scopus 로고
    • Analysis of long-term persistence mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
    • Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Fuller C, et al. Analysis of long-term persistence mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-327.
    • (2011) J Clin Virol , vol.52 , pp. 321-327
    • Susser, S.1    Vermehren, J.2    Forestier, N.3    Welker, M.W.4    Grigorian, N.5    Fuller, C.6
  • 97
    • 84882808984 scopus 로고    scopus 로고
    • Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with HCV genotype 1
    • Epub ahead of print
    • Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, et al. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with HCV genotype 1. J Clin Microbiol 2013. Epub ahead of print.
    • (2013) J Clin Microbiol
    • Akuta, N.1    Suzuki, F.2    Fukushima, T.3    Kawamura, Y.4    Sezaki, H.5    Suzuki, Y.6
  • 98
    • 84856410313 scopus 로고    scopus 로고
    • Antiviral strategies in hepatitis C virus infection
    • Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 Suppl 1: S88-S100.
    • (2012) J Hepatol , vol.56 , Issue.SUPPL. 1
    • Sarrazin, C.1    Hezode, C.2    Zeuzem, S.3    Pawlotsky, J.M.4
  • 99
    • 84884247234 scopus 로고    scopus 로고
    • Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: Ultra-deep sequencing analysis of HCV NS5B genotype-specific region
    • Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, et al. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One 2013; 8: e73615.
    • (2013) PLoS One , vol.8
    • Wu, S.1    Kanda, T.2    Nakamoto, S.3    Jiang, X.4    Miyamura, T.5    Nakatani, S.M.6
  • 100
    • 84871661723 scopus 로고    scopus 로고
    • Current prospects for interferon-free treatment of hepatitis C in 2012
    • Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013; 28: 38-45.
    • (2013) J Gastroenterol Hepatol , vol.28 , pp. 38-45
    • Stedman, C.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.